Clinical trials: Cancer Colonic
Advanced Solid Tumors, Carcinoid
Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)
The purpose of this protocol is to allow continued treatment with conatumumab and/or ganitumab, with or without chemotherapy, to participants who completed a separate Amgen-sponsored conatumumab or ganitumab study without disease…
- Conditions
- Advanced Solid Tumors, Carcinoid, Colorectal Cancer, Locally Advanced
- Trial name
- NCT01327612
- Testing
- Modified FOLFOX6, Conatumumab, Ganitumab
- Where
- 12 sites in United States, Poland and 1 more
- Volunteers
- 12 people
- Sponsor
- Amgen
Solid Tumor, Adult
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
This is a phase 1/1b study of TTX-030 in combination therapy, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive…
- Trial name
- NCT04306900
- Testing
- TTX-030, budigalimab and mFOLFOX6, TTX-030, budigalimab and docetaxel, TTX-030 and mFOLFOX6
- Where
- 32 sites in United States, South Korea
- Volunteers
- 185 people
- Sponsor
- Trishula Therapeutics, Inc.
Colorectal Cancer
To Determine the Safety of Regorafenib, Hydroxychloroquine, and Entinostat Metastatic Colorectal Cancer
The main purpose of this study is to find the best dose of hydroxychloroquine (HCQ) when given in combination with regorafenib and entinostat.
- Trial name
- NCT03215264
- Testing
- hydroxychloroquine, entinostat, regorafenib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Colorectal Cancer
Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer
The investigators propose to assess the efficacy, progression-free survival, and adverse events of pacritinib in patients with refractory colorectal cancer.
- Trial name
- NCT02277093
- Testing
- Pacritinib
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Washington University School of Medicine
Colorectal Cancer
PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study
The purpose of this study is to assess whether treatment with the study drug, panitumumab given concomitantly with every 2 (Q2) week oxaliplatin-based chemotherapy and bevacizumab improves progression-free survival (PFS) compared…
- Trial name
- NCT00115765
- Testing
- Oxaliplatin Based Chemotherapy, Panitumumab, Irinotecan Based Chemotherapy
- Volunteers
- 1,053 people
- Sponsor
- Amgen
Colorectal Cancer
Impact of Family History and Decision Support on High-risk Cancer Screening
Family health history can help identify patients at higher than average risk for disease. There is no standardized system for collecting and updating family health history, using this information to determine a patient's disease…
- Trial name
- NCT02247336
- Testing
- Family health history platform (MeTree)
- Where
- 2 sites in United States
- Volunteers
- 505 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Solid Tumor
A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.
This was a clinical study with an orally administered drug, BDTX-189 in participants with advanced solid tumors that had select mutations or alterations in human epidermal growth factor receptor 2 (HER2/ErbB2) genes or epidermal…
- Trial name
- MasterKey-01 (NCT04209465)
- Testing
- BDTX-189
- Where
- 38 sites in United States, Denmark and 2 more
- Volunteers
- 91 people
- Sponsor
- Black Diamond Therapeutics, Inc.
Hepatic Metastases, Colon Cancer
Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combination With Chemotherapy With/Without Bevacizumab for Hepatic Metastases From Colorectal Cancer
The purpose of this study is to determine whether the addition of bevacizumab, to hepatic arterial therapy with floxuridine (FUDR) and dexamethasone (Dex) (regional chemotherapy), and either oxaliplatin or CPT-11, plus…
- Conditions
- Hepatic Metastases, Colon Cancer, Rectal Cancer
- Trial name
- NCT00200200
- Testing
- Bevacizumab HAI plus systemic chemotherapy, HAI plus systemic chemotherapy
- Where
- 5 sites in United States
- Volunteers
- 73 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Colon Cancer, Rectal Cancer
Lymphoseek® as Lymphoid Tissue Targeting Agents in Colon Cancer(CNC)
45 patients undergoing a colon (large bowel/intestine)removal operation for the diagnosis of colon cancer will be included in this study. During colon operation the affected portion of the colon is removed.
- Trial name
- NCT01902953
- Testing
- Lymphoseek and VBD Sln dissection
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Maimonides Medical Center
Cancer Survivor, Stage I Colorectal Cancer AJCC v8
Systems Support Mapping in Guiding Self-Management in Stage I-III Colorectal Cancer Survivors
This pilot trial studies how well systems support mapping works in guiding self-management in stage I-III colorectal cancer survivors.
- Conditions
- Cancer Survivor, Stage I Colorectal Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage IIA Colorectal Cancer AJCC v8
- Trial name
- NCT03520283
- Testing
- Interview, Questionnaire Administration, System Support Mapping
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Wake Forest University Health Sciences
Colorectal Cancer
Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX)
The primary purpose of this study is to compare the efficacy of AZD2171 in combination with FOLFOX to the efficacy of bevacizumab in combination with FOLFOX, in the second-line treatment of patients with metastatic colorectal…
- Trial name
- HORIZON I (NCT00278889)
- Testing
- AZD2171, 5-fluorouracil, Leucovorin
- Where
- 43 sites in Austria, Belgium and 7 more
- Volunteers
- 215 people
- Sponsor
- AstraZeneca
Colonic Cancer
Evaluating Online Messages About Colon Cancer Screening
The goal of the study is to determine, using a choice-based approach, what messages (pulled from various online sites) people find more and less persuasive and shareable on the topic of colorectal cancer screening.
- Trial name
- NCT06134089
- Testing
- Perceived Effectiveness Prompt, Perceived Shareability Prompt
- Where
- United States
- Volunteers
- 2,210 people, healthy volunteers welcome
- Sponsor
- University of Utah
Colorectal Cancer
Promoting Veteran-Centered Colorectal Cancer Screening
Systematic efforts to improve colorectal cancer screening use in the VA Healthcare System have resulted in an increase in not only appropriate, but also inappropriate use of screening.
- Trial name
- PROM-IS (NCT02027545)
- Testing
- Decision Aid, Provider Education, Performance Measure Modification
- Where
- United States
- Volunteers
- 436 people
- Sponsor
- VA Office of Research and Development
Recurrent Colorectal Carcinoma, Stage IVA Colorectal Cancer
FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer
This phase II trial studies how well fluorouracil, leucovorin calcium, and irinotecan hydrochloride (FOLFIRI) together with panitumumab work in treating patients with colorectal cancer that expresses the RAS and B-Raf…
- Conditions
- Recurrent Colorectal Carcinoma, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer
- Trial name
- NCT02508077
- Testing
- Fluorouracil, Irinotecan Hydrochloride, Laboratory Biomarker Analysis
- Where
- 4 sites in United States
- Volunteers
- 1 people
- Sponsor
- City of Hope Medical Center
End of Life, Advanced Cancer
Engagement of Patients With Advanced Cancer
The Engagement of Patients with Advanced Cancer is an intervention that utilizes well-trained lay health coaches to engage patients and their families in goals of care and shared decision-making after a diagnosis of advanced…
- Conditions
- End of Life, Advanced Cancer, Lung Neoplasm, Gastric Cancer
- Trial name
- EPAC (NCT02966509)
- Testing
- EPAC
- Volunteers
- 213 people
- Sponsor
- Stanford University
Colorectal Cancer, Metastatic Cancer
Oxaliplatin and Capecitabine With or Without an Hepatic Arterial Infusion With Floxuridine in Treating Patients Who Are Undergoing Surgery and/or Ablation for Liver Metastases Due to Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, capecitabine, and floxuridine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00268463
- Testing
- capecitabine, floxuridine, oxaliplatin
- Where
- 31 sites in United States
- Volunteers
- 22 people
- Sponsor
- NSABP Foundation Inc
Colorectal Neoplasms, Neoplasms
Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors
This study determined the maximum tolerated dose and safety of SU011248 (sunitinib malate, SUTENT) in combination with FOLFOX [Leucovorin + Fluorouracil (5-FU) + Oxaliplatin].
- Trial name
- NCT00599924
- Testing
- sunitinib + FOLFOX
- Where
- 3 sites in United States
- Volunteers
- 53 people
- Sponsor
- Pfizer
Cancer Screening Tests
Helping Patients and Providers Make Better Decisions About Colorectal Cancer Screening
Precision prevention holds great promise for colorectal cancer (CRC) screening but has not been adequately explored. A patient's chance of having an advanced colorectal neoplasm (ACN), i.e.
- Trial name
- NCT04683731
- Testing
- Decision aid without personalized message, Decision aid with personalized message, Provider notification without personalized message
- Where
- 2 sites in United States
- Volunteers
- 1,111 people
- Sponsor
- Indiana University
Colorectal Cancer With Non Resectable Hepatic Metastasis
Intra-arterial Hepatic Beads Loaded With Irinotecan With Concomitant Chemotherapy With FOLFOX in Patients With Colorectal Cancer With Unresectable Liver Metastases: a Phase II Multicenter Study
Treatment of patients with colorectal cancer having liver metastases is currently based on systemic chemotherapy. Triple therapy with 5FU, oxaliplatin and irinotecan intravenously was effective in terms of response and secondary…
- Trial name
- NCT01839877
- Testing
- HIA DEBIRI + systemic FOLFOX
- Where
- 9 sites in France
- Volunteers
- 58 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Adult Giant Cell Glioblastoma, Adult Glioblastoma
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
The purpose of the study is to conduct research of a new PET radiopharmaceutical in cancer patients. The uptake of the novel radiopharmaceutical 18F-FPPRGD2 will be assessed in study participants with glioblastoma multiforme…
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Male Breast Cancer
- Trial name
- NCT01806675
- Testing
- 18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Sanjiv Sam Gambhir